USPTO Examiner MCINTOSH III TRAVISS C - Art Unit 1693

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18988105ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOFDecember 2024July 2025Allow710NoNo
18828652MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USINGSeptember 2024April 2025Allow720NoNo
18672651Modified Nucleoside PhosphoramiditesMay 2024June 2025Allow1310NoNo
18597197MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USINGMarch 2024April 2025Abandon1310NoNo
18594712MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USINGMarch 2024April 2025Abandon1310NoNo
18441882CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATIONFebruary 2024October 2025Allow2010NoNo
18422333PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOFJanuary 2024September 2025Abandon1910NoNo
18417807COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSIONJanuary 2024April 2025Allow1510NoNo
18410236COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONSJanuary 2024January 2025Allow1310NoNo
18403174Sugar Derivatives and Uses Thereof to Prepare Novel Senolytic AgentsJanuary 2024May 2025Abandon1610NoNo
18390347N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETODecember 2023January 2025Allow1310NoNo
18515359PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOFNovember 2023June 2025Allow1910NoNo
185101286-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONSNovember 2023January 2025Abandon1410NoNo
18503499HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3November 2023December 2024Abandon1410NoNo
18501779COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSIONNovember 2023August 2024Allow900NoNo
18492972PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOFOctober 2023June 2025Allow1910NoNo
18286151NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISMOctober 2023October 2024Abandon1210YesNo
18378097GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITYOctober 2023January 2025Allow1520NoNo
18477379METHODS OF SEQUENCING USING NUCLEOTIDES WITH 3' ACETAL BLOCKING GROUPSeptember 2023December 2024Allow1520NoNo
18467985ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAMESeptember 2023November 2024Allow1410NoNo
18242688METHOD FOR PURIFYING A SODIUM ALGINATE POWDER FROM ENDOTOXINS AND ENDOGENOUS PYROGENSSeptember 2023January 2026Allow2800NoNo
18240621OLIGOSACCHARIDE ANALYTICAL STANDARDSAugust 2023July 2024Allow1010NoNo
18264751HYDROXYHETEROCYCLOALKANE-CARBAMOYL DERIVATIVESAugust 2023January 2025Allow1710NoNo
18359297COMPOUNDS AND METHODS FOR TREATING DISEASEJuly 2023August 2024Allow1331YesNo
18272466PHARMACEUTICAL COMPOSITION FOR TREATING SEPSIS AND USE THEREOFJuly 2023February 2026Allow3210NoNo
18350195CONJUGATED ANTISENSE COMPOUNDS AND THEIR USEJuly 2023December 2024Abandon1810NoNo
18215881SOLID FORMS OF A NUCLEOSIDE ANALOGUE AND USES THEREOFJune 2023February 2026Allow3110NoNo
18270117ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOFJune 2023March 2026Allow3210NoNo
18257815METHODS OF TREATING MASTITIS WITH AN ORTHOSOMYCIN ANTIMICROBIAL COMPOUNDJune 2023January 2026Allow3110NoNo
18335136METHOD FOR PREPARING N-ACETYL-D-GALACTOSAMINE TRIPOLYMER PRECURSORJune 2023October 2025Allow2800NoNo
18208629UTILITY OF NEMATODE SMALL MOLECULESJune 2023August 2024Allow1410NoNo
18266438GLYCOSYLATED HISTONE DEACETYLASE INHIBITORS AND METHODS OF MAKING AND USING THE SAMEJune 2023February 2026Allow3210NoNo
18330293CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON’S DISEASEJune 2023October 2024Allow1610NoNo
18256058SYNTHESIS OF ANTIVIRAL NUCLEOSIDESJune 2023March 2026Allow3310NoNo
18143533ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOFMay 2023September 2024Allow1721NoNo
18251273GALECTIN-3 INHIBITING 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVESMay 2023January 2025Allow2010NoNo
18140705YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONSApril 2023March 2026Abandon3410NoNo
18309773COMPOUND INCLUDING A HETEROATOM AND NUCLEOBASEApril 2023March 2026Abandon3510NoNo
18297398CRYSTALLINE FORMS OF A CD73 INHIBITOR AND USES THEREOFApril 2023December 2023Allow820YesNo
18248007SPIRO DERIVATIVES OF ALPHA-D-GALACTOPYRANOSIDESApril 2023January 2025Allow2210NoNo
181926093-PHENOXYBENZOIC ACID-GLUCURONIC ACID CONJUGATE, AND PREPARATION METHOD AND USE THEREOFMarch 2023December 2025Allow3310NoNo
18190171METHOD FOR PRODUCING HYDROXYALKYL ALKYL CELLULOSEMarch 2023November 2025Allow3110YesNo
18040309SOPHOROLIPID-CONTAINING COMPOSITION HAVING EXCELLENT HANDLEABILITYMarch 2023February 2026Allow3701NoNo
18123645HYALURONAN CONJUGATEMarch 2023March 2025Allow2330YesNo
18044089SPERM MOTILITY IMPROVING AGENT AND SPERM MOTILITY IMPROVING METHODMarch 2023January 2026Allow3510NoNo
18174474ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAMEFebruary 2023December 2025Allow3310NoNo
181727195'-MODIFIED CARBOCYCLIC RIBONUCLEOTIDE DERIVATIVES AND METHODS OF USEFebruary 2023January 2026Allow3520NoNo
180219072',3'-Diacetyluridine Substituted With Acetoacetyl at the 5' PositionFebruary 2023November 2025Allow3310NoNo
18021753PROMOIETY STRATEGY TO ENHANCE DRUG ACTIVITYFebruary 2023January 2026Allow3510NoNo
18100192SYNTHESIS OF AN ANTIVIRAL AZASUGAR TRIPHOSPHATEJanuary 2023October 2025Allow3310NoNo
180160623-DEOXY-2-KETOALDONIC ACID NITROGEN-CONTAINING DERIVATIVE, PREPARATION METHOD THEREOF, AND USE THEREOFJanuary 2023December 2025Abandon3510NoNo
18015282PHOSPHORAMIDITE SYNTHESIS ON-DEMANDJanuary 2023March 2026Abandon3810NoNo
18085645MODULAR SYNTHESIS OF AMINOGLYCOSIDESDecember 2022June 2024Allow1700NoNo
18068360SULFONE DERIVATIVESDecember 2022October 2025Allow3410NoNo
18010146BRIDGED NUCLEOSIDE AND NUCLEOTIDEDecember 2022September 2025Allow3410NoNo
17993937CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOFNovember 2022January 2026Allow3720NoNo
17927426GALECTIN-3 INHIBITORSNovember 2022January 2025Allow2610NoNo
17999080PREPARATION METHOD OF 2'-SUBSTITUTED PYRIMIDINE NUCLEOSIDENovember 2022January 2026Abandon3810NoNo
17998261SMALL MOLECULE INHIBITORS OF GALECTIN-3November 2022January 2025Allow2610NoNo
17998295PROCESSES FOR PREPARING C-4 SUGARS AND KETOSE SUGARSNovember 2022January 2026Allow3910NoNo
17922514PROTEOLYSIS TARGETING COMPOUND WITH TISSUE TARGETING CAPABILITY AND USE THEREOFOctober 2022January 2026Allow3810NoNo
17922229COMPOSITIONS AND METHODS OF USE THEREOFOctober 2022June 2025Allow3100NoNo
17921653SMALL MOLECULE INHIBITORS OF GALECTIN-3October 2022December 2024Allow2610YesNo
17921964HETEROCYCLIC GLP-1 AGONISTSOctober 2022December 2025Abandon3810NoNo
17996613BENZYLOXY PHOSPH(ON)ATE COMPOUNDSOctober 2022October 2025Allow3610NoNo
17964867Green Methods of Carbohydrate AcetylationOctober 2022February 2026Allow4010NoNo
17995945ALKYNYL NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS EOctober 2022November 2025Abandon3810NoNo
17995948SPIROCYCLIC NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF HEPATITIS EOctober 2022November 2025Abandon3810NoNo
17915843POLYMERIC AMPHOTERIC SURFACTANT COMPOUNDSeptember 2022August 2025Allow3410NoNo
17915822METAL-CARBOHYDRATE COMPLEXSeptember 2022August 2025Allow3510NoNo
17913920Methods and Reagents for Synthesizing Nucleosides and Analogues ThereofSeptember 2022January 2026Allow4010NoNo
17932359RNA-Editing Oligonucleotides and Uses ThereofSeptember 2022July 2024Allow2210NoNo
17901771POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATESSeptember 2022March 2025Allow3111YesNo
17905142A METHOD FOR PREVENTING OR TREATING A CORNAVIRUS INFECTIOUS DISEASEAugust 2022February 2026Allow4210NoNo
17801340IMMUNOMODULATING O-HET/ARYL AZALIDESAugust 2022May 2025Allow3310NoNo
17800339CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAMEAugust 2022September 2025Allow3710NoNo
17818856NUCLEIC ACID-PEPTIDE-NUCLEIC ACID CONJUGATE MOLECULES AND METHODS OF MAKING THE SAMEAugust 2022March 2026Allow4311NoNo
177983973'-KETOGLYCOSIDE COMPOUND FOR THE SLOW RELEASE OF A VOLATILE ALCOHOLAugust 2022June 2025Allow3510NoNo
17883398NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANSINE-3', 5'-CYCLIC MONOPHOSPHATESAugust 2022July 2025Allow3610NoNo
17785312USES OF LIPOTEICHOIC ACID FROM BIFIDOBACTERIAJune 2022December 2025Abandon4201NoNo
17784797CONJUGATES BETWEEN A BIOPOLYMER AND A PHOTOACTIVATED ANTIMICROBIAL AGENT FOR COMBATING FUNGAL DISEASES OF AGRICULTURAL INTEREST AND METHODS FOR PRODUCING SAID CONJUGATESJune 2022February 2026Allow4511NoNo
17836763SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOFJune 2022August 2024Allow2620NoNo
17831461PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOFJune 2022September 2025Allow3910NoNo
17832112COBALAMIN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF DISEASES CAUSED BY LACK OF VITAMIN B12 SUPPLYJune 2022July 2025Allow3710NoNo
17831460PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOFJune 2022November 2024Allow3010NoNo
17824362Novel Immunodulating Small MoleculesMay 2022December 2025Allow4320NoNo
17779043COMPOSITION FOR PREPARING ALLULOSE AND METHOD FOR PREPARING ALLULOSE BY USING SAMEMay 2022June 2025Allow3710NoNo
17746632TERPENE O-GLYCOSIDESMay 2022September 2024Allow2831NoNo
17771089NUCLEOSIDE DERIVATIVE AND USE THEREOFApril 2022July 2025Allow3910NoNo
17714241MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASEApril 2022December 2024Abandon3321NoNo
17762387PREPARATION METHOD OF A GLYCOSIDE COMPOUNDMarch 2022July 2025Allow4010NoNo
17701399CHROMOGENIC AND FLUOROGENIC COMPOUNDS AND THEIR USE FOR BIOLOGICAL DETECTIONMarch 2022February 2026Allow4711NoNo
17761109SYNTHESIS OF GLYCOSPHINGOLIPIDSMarch 2022December 2025Allow4520NoNo
17694630APOE4 IMPAIRS MYELINATION VIA ALTERED CHOLESTEROL BIOSYNTHESIS AND TRANSPORT IN OLIGODENDROGLIAMarch 2022December 2024Allow3321YesNo
17694180MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOFMarch 2022August 2024Allow2920NoNo
17434331METHOD FOR PRODUCING GLYCAN, BUILDING BLOCK FOR GYLICAN SYNTHESIS, AND COMPOUNDMarch 2022May 2025Allow4410YesNo
17638799ALPHA-D-GALACTOPYRANOSIDE DERIVATIVESFebruary 2022January 2025Allow3510NoNo
17679104METHOD OF PRODUCING NUCLEIC ACID COMPOUND, AND NUCLEIC ACID COMPOUNDFebruary 2022August 2025Allow4110NoNo
176345122-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVESFebruary 2022January 2025Allow3510NoNo
17665724METHODS FOR THE PREPARATION OF RIBOSIDESFebruary 2022August 2025Abandon4210NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCINTOSH III, TRAVISS C.

Strategic Value of Filing an Appeal

Total Appeal Filings
19
Allowed After Appeal Filing
7
(36.8%)
Not Allowed After Appeal Filing
12
(63.2%)
Filing Benefit Percentile
60.5%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 36.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner MCINTOSH III, TRAVISS C - Prosecution Strategy Guide

Executive Summary

Examiner MCINTOSH III, TRAVISS C works in Art Unit 1693 and has examined 327 patent applications in our dataset. With an allowance rate of 96.3%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner MCINTOSH III, TRAVISS C's allowance rate of 96.3% places them in the 86% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MCINTOSH III, TRAVISS C receive 1.80 office actions before reaching final disposition. This places the examiner in the 40% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MCINTOSH III, TRAVISS C is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +3.3% benefit to allowance rate for applications examined by MCINTOSH III, TRAVISS C. This interview benefit is in the 25% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 32.8% of applications are subsequently allowed. This success rate is in the 70% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 63.1% of cases where such amendments are filed. This entry rate is in the 88% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 88% percentile among all examiners. Of these withdrawals, 72.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 53.8% are granted (fully or in part). This grant rate is in the 54% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 22.0% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.